SINT

1.1304.24%
GR

Gregg Richard Honigblum

Chief Investment Officer & Director

Mr. Gregg Richard Honigblum serves as Chief Investment Officer at Sintx Technologies, Inc. since April 2025. He was Chief Strategy Officer of Sintx Technologies, Inc. from November 2024 until April 2025 and serves as its Director from April, 2025. Mr. Honigblum has been a long-time supporter of SINTX and its predecessor, Amedica. He serves as SINTX's Chief Strategy Officer and has led recent financing efforts, including a successful ATM and PIPE transaction. His background includes investment banking, founding and scaling of medtech companies and extensive experience in capital formation and business strategy. Mr. Honigblum joined the Sintx Technologies, Inc. in December 2006. Mr. Honigblum was Co-Founder, Chief Revenue Officer and Manager of HealthGrowth Capital, LLC until 2025. He is a Managing Director at Westlake Securities, LLC. Mr. Honigblum joined Westlake Securities in 2014 as a Managing Director leading the private equity group focusing on biotechnology, medical devices, diagnostics and pharmaceuticals. He is a part of the investment banking team. He was the Chief Executive Officer of Creation Capital LLC since 2001 and Creation Capital Advisors, LLC. His most recent successes include Myriad Genetics (MYGN), which grew from a startup in 1992 to a major player in the genomics arena and reached a valuation over 2.5 Billion in seven years. In 1995, as a co-founder and investment banker of Acacia Biosciences he was successful in securing the first three rounds of financing. He served as a Director of Amedica Corporation from December 2006 to September 2013. Mr. Honigblum has raised over 500 million in private equity and has been instrumental in providing early stage capital for companies. Mr. Honigblum has financial and Wall Street experience. For the past many years he has played a major role in all phases of development of several high technology companies with an emphasis on biotechnology. Mr. Honigblum has years of experience as a financier for emerging growth companies primarily in the healthcare area. He holds a B.A. in Economics at the University of Texas at Austin in 1985 and attended the Pepperdine Graduate School of Business from 1988 to 1990.

Positions